Boning Zhang

Boning Zhang

Auto-generated profile, based on publicly available information

Boning Zhang

Department of Chemistry and Institute for Drug Discovery Purdue University West Lafayette IN 47907 USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Cell
Verified
Journal Article
Closed access
XWXiaoqing Wang
Xiaoqing Wang
CTCollin Tokheim
Collin Tokheim
SGShengqing Stan Gu
Shengqing Stan Gu
BWBinbin Wang
Binbin Wang
QTQin Tang
Qin Tang
XLX. Shirley Liu
X. Shirley Liu

1 October 2022 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
WZWubing Zhang
Wubing Zhang
SBShourya S. Roy Burman
Shourya S. Roy Burman
JCJiaye Chen
Jiaye Chen
KDKatherine A. Donovan
Katherine A. Donovan
Yang CaoYang Cao
Yang Cao
XLX. Shirley Liu
X. Shirley Liu
Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell’s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed “degradability”, is largely unknown. Here, we developed a machine learning model, model-free analysis of protein degradability (MAPD), to predict degradability from features intrinsic to protein targets. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds [with an area under the precision–recall curve (AUPRC) of 0.759 and an area under the receiver operating characteristic curve (AUROC) of 0.775] and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By structural modeling, we found that E2-accessible ubiquitination sites, but not lysine residues in general, are particularly associated with kinase degradability. Finally, we extended MAPD predictions to the entire proteome to find 964 disease-causing proteins (including proteins encoded by 278 cancer genes) that may be tractable to TPD drug development.

27 January 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JNJohn Victor Napoleon
John Victor Napoleon
BZBoning Zhang
Boning Zhang
QLQian Luo
Qian Luo
MSMadduri Srinivasarao
Madduri Srinivasarao
Philip LowPhilip Low
Philip Low

30 October 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
BZBoning Zhang
Boning Zhang
JNJohn Victor Napoleon
John Victor Napoleon
XLXin Liu
Xin Liu
QLQian Luo
Qian Luo
MSMadduri Srinivasarao
Madduri Srinivasarao
Philip LowPhilip Low
Philip Low
Background: Most adoptive cell therapies (ACTs) suffer from an inability to control the therapeutic cell’s behavior following its transplantation into a patient. Thus, efforts to inhibit, activate, differentiate or terminate an ACT after patient reinfusion can be futile, because the required drug adversely affects other cells in the patient. Methods: We describe here a two domain fusion receptor composed of a ligand-binding domain linked to a recycling domain that allows constitutive internalization and trafficking of the fusion receptor back to the cell surface. Because the ligand-binding domain is designed to bind a ligand not normally present in humans, any drug conjugated to this ligand will bind and endocytose selectively into the ACT. Results: In two embodiments of our strategy, we fuse the chronically endocytosing domain of human folate receptor alpha to either a murine scFv that binds fluorescein or human FK506 binding protein that binds FK506, thereby creating a fusion receptor composed of largely human components. We then create the ligand-targeted drug by conjugating any desired drug to either fluorescein or FK506, thereby generating a ligand-drug conjugate with ~10-9 M affinity for its fusion receptor. Using these tools, we demonstrate that CAR T cell activities can be sensitively tuned down or turned off in vitro as well as tightly controlled following their reinfusion into tumor-bearing mice. Conclusions: We suggest this ‘chimeric endocytosing receptor’ can be exploited to manipulate not only CAR T cells but other ACTs following their reinfusion into patients. With efforts to develop ACTs to treat diseases including diabetes, heart failure, osteoarthritis, cancer and sickle cell anemia accelerating, we argue an ability to manipulate ACT activities postinfusion will be important.

27 January 2022 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
JNJohn Victor Napoleon
John Victor Napoleon
BZBoning Zhang
Boning Zhang
QLQian Luo
Qian Luo
MSMadduri Srinivasarao
Madduri Srinivasarao
Philip LowPhilip Low
Philip Low